Fig. 3: BCL-XL is crucial for stem cell survival in patient-derived adenoma and tumor organoids.
From: BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer
a, b Graphs depict relative outgrowth of human tubular adenomas TA1 and TA5 quantified 3 days after passaging, upon treatment with indicated doses of a ABT-199 or b A-1155463. Each dot represents a replicate (minimal n = 6 per condition, n = 3 independent experiments), error bars indicate s.e.m. *p < 0.05, **p < 0.01, ****p < 0.0001, ordinary one-way ANOVA. c Cleaved caspase-3 stained human TAs after 24 h treatment with 300 nM ABT-199 or A-1155463. Scale bars, 250 µm. d Graphs depict relative outgrowth of human tubular adenomas TA1 and TA5 quantified 3 days after passaging, upon treatment with indicated doses of AZD5991. Each dot represents a replicate (minimal n = 6 per condition, n = 3 independent experiments), error bars indicate s.e.m. e Relative viability of patient-derived CRC organoids upon treatment with a titration of ABT-199 (orange), A-1155463 (green), or AZD5991 (blue) (n = 3 independent experiments). Error bars indicate s.e.m.
